Cardiovascular Disease Management

Medication Dosage and Administration

The American College of Cardiology recommends diltiazem dosing at 180-360 mg once daily using extended-release formulations for hypertension, with higher doses of 360-480 mg daily often required for optimal blood pressure control 1
For angina, diltiazem is recommended at 30-90 mg immediate-release four times daily or 120-360 mg once daily using extended-release formulations, as suggested by the American Heart Association 2
Calcium channel blockers, such as diltiazem, can be used to treat hypertension and angina, with recommended starting doses of 240mg once-daily extended-release formulation and maintenance ranges of 120-360mg once daily, as suggested by the American College of Cardiology 3, 4, 2, 5

Diltiazem use is associated with common side effects including hypotension, dizziness, flushing, bradycardia, and edema, according to the American College of Cardiology 1
Diltiazem is contraindicated in patients with left ventricular dysfunction (LVEF <40%), decompensated heart failure, AV block greater than first degree, sick sinus syndrome, cardiogenic shock, and pre-excitation syndromes (e.g., Wolff-Parkinson-White syndrome) 6, 7, 8, 9, 10
Non-dihydropyridine calcium channel blockers like diltiazem may have a detrimental effect on mortality in patients with left ventricular dysfunction, according to the American College of Cardiology 1
Combination therapy of beta-blockers with non-dihydropyridine calcium channel blockers (like diltiazem) increases the risk of bradycardia and heart block, requiring careful monitoring, as recommended by the American College of Cardiology and American Heart Association 11, 12

Patients on diltiazem should be monitored for blood pressure response, heart rate and cardiac conduction, signs of fluid retention (edema), and symptoms of hypotension or bradycardia, with common side effects including hypotension, dizziness, flushing, bradycardia, and edema, as recommended by the American College of Cardiology and American Heart Association 2, 11, 13, 14, 15
Continuous cardiac monitoring is necessary to assess for worsening bradycardia or conduction abnormalities, and to monitor blood pressure for hypotension, as recommended by the American College of Cardiology 13
Patients with cognitive impairment or history of medication misuse may require supervised administration of diltiazem, and medical department nurses should determine whether patients have the necessary skill and responsible behavior to be allowed self-administration, as recommended by the American Diabetes Association 16, 17

For rate control in atrial fibrillation with LV dysfunction, the European Society of Cardiology recommends using beta-blockers or digoxin instead of diltiazem 18
For hypertension with LV dysfunction, the European Society of Cardiology recommends using ACE inhibitors, ARBs, or dihydropyridine calcium channel blockers instead of diltiazem 9
For angina with LV dysfunction, the European Society of Cardiology recommends using nitrates and beta-blockers instead of diltiazem 9
Electrophysiology study and catheter ablation should be considered as definitive treatment if the patient has recurrent SVT, with success rates for ablation of AVNRT exceeding 95% with low complication rates, as recommended by the American College of Cardiology 13, 19

Patients on multiple doses of short-acting oral medications, such as calcium channel blockers like diltiazem, should be placed in a 'keep on person' program when feasible and consistent with security concerns, to ensure consistent dosing throughout the day, as recommended by the American Diabetes Association 16
The European Society of Cardiology recommends withdrawing diltiazem in patients taking sodium channel blockers who present with atrial flutter with 1:1 AV conduction, due to potential risks 20
Diltiazem should be used with caution in patients with risk factors for QT prolongation and torsades de pointes, as outlined in the following table: